• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Etoricoxib Dexcel
    / Dexcel


    Active Ingredient
    Etoricoxib 30, 60, 90, 120 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Tablets

    28 X 30 mg

    not in the basket chart 74261

    Tablets

    14 X 60 mg

    not in the basket chart 74262

    Tablets

    14 X 90 mg

    not in the basket chart 74263

    Tablets

    7 X 120 mg

    not in the basket chart 74265

    Related information


    Dosage

    As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient’s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.
    Osteoarthritis: The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.
    Rheumatoid arthritis: The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.
    Ankylosing spondylitis: The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.
    Acute pain conditions: For acute pain conditions, etoricoxib should be used only for the acute symptomatic period.
    Acute gouty arthritis: The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, etoricoxib was given for 8 days.
    Postoperative dental surgery pain: The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require other postoperative analgesia in addition to Etoricoxib Dexcel during the three day treatment period. Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore: The dose for OA should not exceed 60 mg daily. The dose for RA and ankylosing spondylitis should not exceed 90 mg daily. The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days treatment. The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a maximum of 3 days.


    Indications

    ETORICOXIB DEXCEL 30 mg: For the symptomatic relief of osteoarthritis (OA).
    ETORICOXIB DEXCEL 60 mg: For the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis.
    ETORICOXIB DEXCEL 90 mg: For the symptomatic relief of rheumatoid arthritis (RA) and ankylosing spondylitis. For the short-term treatment of moderate pain associated with dental surgery.
    ETORICOXIB DEXCEL 120 mg: For the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.


    Contra-Indications

    Hypersensitivity to the active substance or to any of the excipients. Active peptic ulceration or active gastro-intestinal (GI) bleeding. Patients who, after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors, experience bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions. Pregnancy and lactation. Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10). Estimated renal creatinine clearance <30 ml/min. Children and adolescents under 16 years of age. Inflammatory bowel disease. Congestive heart failure (NYHA II-IV). Patients with hypertension whose blood pressure is persistently elevated above 140/90 mmHg and has not been adequately controlled. Established ischaemic cardiac disease, peripheral arterial disease, and/or cerebrovascular disease.


    Manufacturer
    Dexcel Ltd.
    Licence holder
    CLOSE